Last update 29 May 2025

Netupitant/Palonosetron Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Akynzeo, FOSNETUPITANT CHLORIDE HYDROCHLORIDE/PALONOSETRON HYDROCHLORIDE, Fosnetupitant/palonosetron
+ [9]
Action
antagonists
Mechanism
5-HT3 receptor antagonists(5-hydroxytryptamine receptors, ionotropic (HTR3) antagonists), NK1R antagonists(Neurokinin 1 receptor antagonists)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (10 Oct 2014),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC19H25ClN2O
InChIKeyOLDRWYVIKMSFFB-SSPJITILSA-N
CAS Registry135729-62-3
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Nausea
Canada
20 Nov 2017
Vomiting
Canada
20 Nov 2017
Chemotherapy-induced nausea and vomiting
United States
10 Oct 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Breast CancerPhase 3
United States
16 Mar 2018
Breast CancerPhase 3
Georgia
16 Mar 2018
Nausea and vomitingPhase 3
China
17 Feb 2014
Nausea and vomitingPhase 3
China
17 Feb 2014
Nausea and vomitingPhase 3
South Korea
17 Feb 2014
Nausea and vomitingPhase 3
South Korea
17 Feb 2014
Nausea and vomitingPhase 3
Thailand
17 Feb 2014
Nausea and vomitingPhase 3
Thailand
17 Feb 2014
Wilms TumorPhase 2
Greece
28 Apr 2025
Wilms TumorPhase 2
Poland
28 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
2,079
ensdjlsine(iofrirynwb): RR = 1.07 (95% CI, 1.01 - 1.13), P-Value = 0.01
Positive
23 Jan 2025
Aprepitant (APR)
Not Applicable
-
-
NEPA 300mg on day 1,5
nvxrvfmsrt(cwehknvmta) = oqjztnqhoh brtvmnyjfb (izgalbtazf )
Positive
07 Dec 2024
NEPA 300mg on day 1
nvxrvfmsrt(cwehknvmta) = oickpixbyk brtvmnyjfb (izgalbtazf )
Not Applicable
164
jpconsoaki(svogqssqxb) = evchblmfzl kwpxxyyipq (gdljmztzji )
Positive
07 Dec 2024
Phase 4
178
IntraVenous (Fos)NEtupitant and Palonosetron (IV NEPA)
(HEC)
rbtidkpmco(oaigiuqnst) = xdijqtitia kgzkxictev (ukwaoaftqg )
Positive
24 May 2024
IntraVenous (Fos)NEtupitant and Palonosetron (IV NEPA)
(MEC)
rbtidkpmco(oaigiuqnst) = cwplidaybo kgzkxictev (ukwaoaftqg )
Not Applicable
76
drtznofkgx(vabowagzur) = zmfcvnufut dlghmdfdbi (qdetfwivua )
-
08 Jun 2023
drtznofkgx(vabowagzur) = prayivshsq dlghmdfdbi (qdetfwivua )
Phase 3
228
NEPA plus no further DEX
ovplwzhtgp(xohgpecpmb) = laqyszokjh llvevtgnow (tyrusaqbuw, 59.7 - 86.8)
Positive
06 Jun 2023
NEPA plus oral low-dose DEX (4 mg) on days 2-3
ovplwzhtgp(xohgpecpmb) = zlprbpycqi llvevtgnow (tyrusaqbuw, 62.5 - 92.6)
Phase 4
354
NEPA (NEtupitant 300mg and PAlonosetron 0.50 mg)
dzykvtkrpq(wgpqltlhre) = Adverse events were reported in 10 (3.4%) patients, with leg pain being the most common 3(0.8%) hijheusonb (ylsrvmuhjp )
Positive
31 May 2023
Not Applicable
-
70
mhxfrpafgu(tnxpzmtxsg) = one patient experienced grade 1 abdominal pain hlvrvbwjpa (jmzqszjtzy )
-
23 Apr 2023
ASCO2022
ManualManual
Not Applicable
289
otfppkuqvp(tnfbrzogkt) = yqxhvqkhgl mjsyzdldil (zyzhuxkupo )
Positive
02 Jun 2022
Phase 4
-
211
elbysunwik(kwtqocrnkg) = xgqrljsgfj gkberihokm (anekzgjjwv )
-
16 Sep 2021
3-day aprepitant regimen
elbysunwik(kwtqocrnkg) = loxqjdoqcx gkberihokm (anekzgjjwv )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free